Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701440 | 0.83 | ALDH1A1 (0.42) | LMNAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL15165286 | 0.82 | MAPT (0.39) | LMNAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1699400 | 0.82 | KDM4E (0.41) | LMNAALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL1699649 | 0.80 | PTGDR2 (0.43) | LMNAALDH1A1MAPTSMN1; SMN2TP53 | |
| SCHEMBL1699415 | 0.77 | PTGDR2 (0.41) | LMNAPLA2G2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15165189 | 0.75 | CYP3A4 (0.41) | KMT2APLA2G2APTGDR2MAP2FABP3 | |
| SCHEMBL1699452 | 0.75 | CYP3A4 (0.50) | PLA2G2APTGDR2FABP3FABP4 | |
| SCHEMBL15334224 | 0.74 | SMN1; SMN2 (0.43) | KMT2AMEN1TACR3ALDH1A1NPC1 | |
| SCHEMBL15334221 | 0.74 | SMN1; SMN2 (0.43) | KMT2AMEN1TACR3ALDH1A1NPC1 | |
| SCHEMBL10272102 | 0.74 | PTGDR2 (0.37) | LMNAKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2588450-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | NFATC1, AADAT, ACAT1 | LMNA 710/4885KMT2A 375/4885MEN1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.